DNLI
Price
$13.83
Change
-$0.17 (-1.21%)
Updated
Jul 21 closing price
Capitalization
2.01B
9 days until earnings call
RYTM
Price
$88.63
Change
-$0.57 (-0.64%)
Updated
Jul 21 closing price
Capitalization
5.85B
14 days until earnings call
Interact to see
Advertisement

DNLI vs RYTM

Header iconDNLI vs RYTM Comparison
Open Charts DNLI vs RYTMBanner chart's image
Denali Therapeutics
Price$13.83
Change-$0.17 (-1.21%)
Volume$1.16M
Capitalization2.01B
Rhythm Pharmaceuticals
Price$88.63
Change-$0.57 (-0.64%)
Volume$668.07K
Capitalization5.85B
DNLI vs RYTM Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. RYTM commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and RYTM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (DNLI: $13.83 vs. RYTM: $88.63)
Brand notoriety: DNLI and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 77% vs. RYTM: 87%
Market capitalization -- DNLI: $2.01B vs. RYTM: $5.85B
DNLI [@Biotechnology] is valued at $2.01B. RYTM’s [@Biotechnology] market capitalization is $5.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileRYTM’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • RYTM’s FA Score: 1 green, 4 red.
According to our system of comparison, RYTM is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while RYTM’s TA Score has 6 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 5 bearish.
  • RYTM’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, RYTM is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -5.85% price change this week, while RYTM (@Biotechnology) price change was -0.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.37%. For the same industry, the average monthly price growth was +15.66%, and the average quarterly price growth was +33.77%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

RYTM is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($5.85B) has a higher market cap than DNLI($2.01B). RYTM YTD gains are higher at: 58.324 vs. DNLI (-32.139). RYTM has higher annual earnings (EBITDA): -145.8M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. RYTM (314M). RYTM has less debt than DNLI: RYTM (4.06M) vs DNLI (48.6M). RYTM has higher revenues than DNLI: RYTM (137M) vs DNLI (0).
DNLIRYTMDNLI / RYTM
Capitalization2.01B5.85B34%
EBITDA-505.16M-145.8M346%
Gain YTD-32.13958.324-55%
P/E RatioN/AN/A-
Revenue0137M-
Total Cash818M314M261%
Total Debt48.6M4.06M1,196%
FUNDAMENTALS RATINGS
DNLI vs RYTM: Fundamental Ratings
DNLI
RYTM
OUTLOOK RATING
1..100
524
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
98
Overvalued
PROFIT vs RISK RATING
1..100
10023
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
6336
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNLI's Valuation (93) in the Biotechnology industry is in the same range as RYTM (98). This means that DNLI’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (23) in the Biotechnology industry is significantly better than the same rating for DNLI (100). This means that RYTM’s stock grew significantly faster than DNLI’s over the last 12 months.

DNLI's SMR Rating (94) in the Biotechnology industry is in the same range as RYTM (100). This means that DNLI’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Price Growth Rating (36) in the Biotechnology industry is in the same range as DNLI (63). This means that RYTM’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as RYTM (100). This means that DNLI’s stock grew similarly to RYTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIRYTM
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 13 days ago
77%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
79%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SFECX23.97N/A
N/A
NAA Large Core C
PKSAX51.91N/A
N/A
Virtus KAR Small-Cap Core A
FZAIX56.41N/A
N/A
Fidelity Advisor International Discv Z
JGEFX12.80N/A
N/A
JHancock Global Equity I
KNGLX11.57-0.04
-0.34%
Vest S&P500 Div Aristocrats Trgt Inc Inv

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-1.21%
NRIX - DNLI
60%
Loosely correlated
+0.36%
BEAM - DNLI
58%
Loosely correlated
+1.35%
OCUL - DNLI
55%
Loosely correlated
+1.63%
DAWN - DNLI
55%
Loosely correlated
N/A
RGNX - DNLI
55%
Loosely correlated
+4.04%
More